CD274 and non-small cell lung carcinoma: Antibodies targeting PD-1 (e.g., nivolumab, pembrolizumab) and PD-L1 (e.g., atezolizumab, avelumab, durvalumab) have demonstrated potent antitumor effects in multiple cancers, including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, and colorectal cancer [91–96].